Ergocalciferol in Chronic Kidney Disease - Full Text View

Sponsored by:	Saint Louis VA Medical Center
Information provided by:	Saint Louis VA Medical Center
ClinicalTrials.gov Identifier:	NCT00411294

Purpose

To examine the effect of ergocalciferol treatment on 25-hydroxyvitamin D and PTH levels in patients with CKD stage 3 and 4

Condition
Chronic Kidney Disease

Drug Information available for: Ergocalciferol

U.S. FDA Resources

Study Type:	Observational
Study Design:	Longitudinal, Defined Population, Retrospective Study
Official Title:	The Effect of Ergocalciferol Treatment on 25-Hydroxyvitamin D Levels and Plasma Intact PTH in Patients With Chronic Kidney Disease Stage 3 and 4

Eligibility

Ages Eligible for Study:	18 Years to 80 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patient with CKD stage 3 or 4 whose 25-hydroxyvitamin D levels are below 30 ng/ml and plasma intact PTH levels >70 pg/ml.

Exclusion Criteria:

Patients who are on any form of active vitamin treatment

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00411294

Locations

United States, Missouri
Saint Louis VA Medical Center
Saint Louis, Missouri, United States, 63104

Sponsors and Collaborators

Saint Louis VA Medical Center

Investigators

Principal Investigator:

Ziyad Al-Aly, M.D.

VAMC-Saint Louis

More Information

No publications provided by Saint Louis VA Medical Center

Additional publications automatically indexed to this study by National Clinical Trials Identifier (NCT ID):

Al-Aly Z, Qazi RA, Gonzalez EA, Zeringue A, Martin KJ. Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD. Am J Kidney Dis. 2007 Jul;50(1):59-68.

Study ID Numbers:	ZA-01
Study First Received:	December 11, 2006
Last Updated:	December 11, 2006
ClinicalTrials.gov Identifier:	NCT00411294 History of Changes
Health Authority:	United States: Federal Government

Keywords provided by Saint Louis VA Medical Center:

ergocalciferol
chronic kidney disease
secondary hyperparathyroidism
vitamin D deficiency

Study placed in the following topic categories:

Vitamin D Deficiency
Renal Insufficiency
Kidney Failure, Chronic
Ergocalciferols
Trace Elements
Bone Density Conservation Agents
Hydroxycholecalciferols
Hyperparathyroidism, Secondary
Vitamin D

Hyperparathyroidism
Urologic Diseases
Renal Insufficiency, Chronic
Vitamins
Neoplasm Metastasis
Micronutrients
Kidney Diseases
Kidney Failure

Additional relevant MeSH terms:

Renal Insufficiency
Growth Substances
Physiological Effects of Drugs
Kidney Failure, Chronic
Ergocalciferols
Bone Density Conservation Agents
Pharmacologic Actions

Urologic Diseases
Renal Insufficiency, Chronic
Vitamins
Kidney Diseases
Micronutrients
Kidney Failure

ClinicalTrials.gov processed this record on May 06, 2009